Yes, daily low-dose Cialis (tadalafil) 5 mg can help reduce the progression of Peyronie's disease, particularly during the active phase.
Based on the most recent 2025 European Association of Urology guidelines, daily tadalafil 5 mg demonstrated lower curvature progression rates and improved symptoms versus controls in patients with Peyronie's disease 1. This represents the highest-quality guideline evidence available and should guide your treatment decision.
Evidence Supporting Use
The mechanism is biologically sound: PDE5 inhibitors like tadalafil may reduce collagen deposition and increase apoptosis in Peyronie's disease plaques 1. Beyond the theoretical benefits, clinical studies demonstrate that tadalafil and sildenafil can improve both pain and erectile function in affected patients 1.
The most compelling recent research comes from a 2024 retrospective study of 191 patients showing that penile curvature progression rate was significantly lower in subjects taking tadalafil 5 mg daily at 12 weeks (25.9% vs. 39.7%, p = 0.042) 2. This study also demonstrated improved erectile function (IIEF-5 scores) and reduced Peyronie's disease-related symptoms, with benefits appearing most pronounced when treatment is initiated early in the active phase.
When to Use It
Timing matters critically. The active disease phase—characterized by pain, deformity deterioration, or progressive curvature—represents the optimal treatment window 1. This is when fibroblast-to-myofibroblast transformation is most pharmacologically accessible 3. Once disease stabilizes (no pain, stable curvature for 3-6 months), the biological rationale weakens.
Practical Implementation
- Dose: 5 mg once daily, taken at approximately the same time each day 4
- Duration: Minimum 12 weeks based on clinical evidence 2, though guidelines suggest continuing through the active phase
- Monitoring: Assess curvature progression, pain levels, and erectile function at baseline and 12-week intervals
Important Caveats
This is not FDA-approved for Peyronie's disease. The FDA label for Cialis lists only erectile dysfunction and benign prostatic hyperplasia as approved indications 4. You're using this off-label based on guideline recommendations and emerging evidence.
Tadalafil works best as part of multimodal therapy. Multiple studies demonstrate superior outcomes when combined with other interventions like intralesional verapamil injections, vacuum erection devices, or penile traction therapy 5, 6, 7. A 2024 study of 445 patients showed that multimodal approaches incorporating tadalafil produced better long-term results than monotherapy 5.
What NOT to Do
The 2025 EAU guidelines explicitly state that oral treatments including pentoxifylline, vitamin E, tamoxifen, procarbazine, potassium para-aminobenzoate, and omega-3 fatty acids are NOT recommended due to lack of proven efficacy 1. These may delay more effective interventions. The 2015 AUA guidelines echo this, noting these therapies constitute a moderate risk/burden by postponing efficacious treatments 8.
Contraindications and Dose Adjustments
Do not use if the patient takes nitrates in any form—this is an absolute contraindication 4. For patients with renal impairment (creatinine clearance 30-50 mL/min), start with 2.5 mg daily and increase to 5 mg based on response 4. For creatinine clearance <30 mL/min or hemodialysis, daily tadalafil is not recommended 4.
Bottom Line Algorithm
- Confirm active disease: Pain, progressive curvature, or deformity worsening
- Rule out contraindications: Nitrate use, severe renal/hepatic impairment
- Initiate tadalafil 5 mg daily (adjust for renal function if needed)
- Consider adding: Penile traction therapy, vacuum device, or intralesional injections for enhanced outcomes
- Reassess at 12 weeks: Measure curvature, pain, erectile function
- Continue through active phase, typically 12-18 months from symptom onset
The evidence supports tadalafil 5 mg daily as a reasonable conservative intervention that may slow disease progression, particularly when started early in the active phase. While not curative, it addresses the underlying pathophysiology and improves quality of life with minimal risk.